

Esteya®

Electronic brachytherapy for treating skin cancer

Esteya electronic brachytherapy. Esteya, a form of high dose rate (HDR) brachytherapy, brings an electronic x-ray source in close proximity to the cancerous site. In this way Esteya can focus more therapeutic radiation on the disease target and minimize radiation to surrounding tissues and organs.

"I think Esteya is the future of skin cancer treatment. I know if I was faced with the choice of having electronic brachytherapy or Mohs micrographic surgery done I would pick Esteya." Douglas Thomas, M.D.,

Dermatologist at Thomas Dermatology Las Vegas, NV USA

A gentle, non-invasive skin cancer treatment

Esteya gives patients and the healthcare team a non-invasive alternative to surgery for treating skin cancer: electronic brachytherapy.

Esteya provides a targeted, yet gentle treatment: precise high dose radiation to the cancerous site, minimized radiation to healthy tissue and a reduced chance of scarring. Because the treatment is short and gentle, patients can expect minimal or no recovery time and may return to their normal daily routine quickly.

Esteya is especially beneficial in treating cosmetically challenging areas, such as the face and scalp, and for areas prone to wound closure problems, such as the back of the hand. Esteya may also be the preferred option for patients for whom surgery presents a high intra-operative or post-operative risk for complications.

Developed in collaboration with a MDT, including dermatologists and radiation oncologists



3 reasons to choose Esteya

PRECISE, TARGETED TREATMENT

The Esteya applicator is placed lightly on the skin, facilitating a precise, focused treatment of the cancerous site: radiation is applied **only where needed.**

All Esteya applicators are equipped with **Tungsten shielding,** minimizing exposure of surrounding, healthy tissue.

The **various applicator sizes** enable treatment of skin lesions of up to 2 cm, even in difficult to reach locations, such as around the nose and eyes.

NON-INVASIVE PROCEDURE

Esteya is a **non-surgical treatment** and uses x-ray radiation (comparable to that used in a dentist's office). Esteya treatment is painless⁹ and doesn't require local anesthesia, making it a very **patient-friendly** procedure.

Esteya treatment is non-invasive, leaves no surgical scars and results in excellent **cosmetic outcome**. Patients are in and out of the clinic quickly and can continue with their normal daily routine.

FAVORABLE TREATMENT TIME

The highly maneuverable Esteya arm and bright LED-guided applicator facilitate **rapid positioning** on the skin cancer site. **Multiple lesions** can be treated in one session, resulting in time-savings for caregivers and patients. Esteya takes just **two to three minutes** per visit to deliver, and treatment* can start within minutes of the patient's arrival at the clinic.

The Esteya treatment planning software comes on a laptop, making **Esteya operation and patient data management very intuitive.**

Esteya electronic brachytherapy

Extra-long, flexible arm

patient comfort

improves positioning and



Automated applicator detection reduces likelihood of human error

Fully automated, once daily QA





Intuitive patient data management allowing patient treatments in only minutes

Tungsten shielded applicators minimize radiation exposure to surrounding tissue



 ${\it *Please check your local regulations for specific requirements}$

Patient-friendly design

reduces anxiety

Designed for use

in a conventional dermatologist treatment room*

^{*}Typical application is 6 to 8 treatment sessions per skin lesion, over a course of 3 to 4 weeks.

Your patients

have options

Electronic brachytherapy with Esteya is the precise, technologically advanced – and gentle – choice to treat skin cancer. With the mobile set-up, the system can be used in a conventional dermatologist treatment room* at any of your clinic locations.

Esteya could be a valuable asset in your dermatology offering and may help you give your patients continued care, all in the same location, your clinic.

Operating Esteya is easy and there's only a short learning curve. Elekta provides a complete training and education program. It's possible to train multiple operators, so clinicians' time in the clinic is efficiently used.




TIME LAPSE

1. Initial lesion

SCALP

- 2. Two weeks after treatment
- 3. Three months after treatment
- 4. Six months after treatment











(Mohs) surgery is the most commonly selected therapy for treating non-melanoma skin cancer among patients. For some patients however, surgery is not an option⁴ or a preference due to concerns about scarring in highly visible areas, challenges in wound closure, or preserving functionality.

High Dose Rate brachytherapy, a well-established technique, has accumulated outstanding results and excellent patient tolerance⁵. Electronic brachytherapy, another form of HDR brachytherapy, is well suited for treating skin lesions, such as basal cell or squamous cell carcinomas.^{6,7,8}

Compared with traditional radiation therapy solutions, electronic brachytherapy can be employed in a much wider range of environments, such as a dermatology clinic, due to the low shielding requirements for low-energy therapeutic x-ray devices.



VISIT ESTEYA.COM

to learn about Esteya set-up, guidelines and read testimonials from healthcare professionals and patients.

*Please check your local regulations for specific requirements

Images and patient cases courtesy of University and Polytechnic Hospital La Fe, Valencia.

Results and outcomes of these patient cases should not be interpreted as a guarantee of similar results. Individual results may vary depending on circumstances and the patient's condition. Availability of Esteya® in target markets is dependent on regulatory admissions and approvals.

7

ABOUT ELEKTA

Elekta's purpose is to invent and develop effective solutions for the treatment of cancer and brain disorders. Our goal is to help our customers deliver the best care for every patient. Our oncology and neurosurgery tools and treatment planning systems are used in more than 6,000 hospitals worldwide. They help treat over 100,000 patients every day. The company was founded in 1974 by Professor Lars Leksell, a physician. Today, with its headquarters in Stockholm, Sweden, Elekta employs around 4,000 people in more than 30 offices across 24 countries. The company is listed on NASDAO OMX Stockholm.

REFERENCES

- [1] Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010 Mar;146(3):279-82.
- [2] Lucas RM, McMichael AJ, Armstrong BK, Smith WT. Estimating the global disease burden due to ultraviolet radiation exposure. *Int J Epidemiol.* 2008 Jun;37(3):654-67. Epub 2008 Feb 14.
- [3] Donaldson MR and Coldiron BM, No End in Sight: The Skin Cancer Epidemic Continues, Semin Cutan Med Surg. 2011 Mar; 30(1):3-5.
- [4] National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Basal Cell Skin Cancers. Version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf, 2014. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Squamous Cell Skin Cancers. Version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf, 2014.
- [5] Alam et al. The use of brachytherapy in the treatment of non-melanoma skin cancer: A review. J Am Acad Dermatol Volume 65, Number 2: 377-388.
- [6] Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy. 2013 Mar-Apr;12(2):134-40.
- [7] Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, et al., "http://www.ncbi.nlm.nih.gov/pubmed/26207112" Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy. 2015 Jun;7(3):231-8.
- [8] Ballester-Sánchez R, Pons-Llanas O, Candela-JuanC, et al., Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachytherapy. 2016 Jan;8(1): 1-8.
- [9] Although radiation therapy is painless, it may cause other side effects: National cancer Institute USA; http://www.cancer.gov/publications/patient-education/skin.pdf

Results and outcomes of patient cases should not be interpreted as a guarantee of similar results. Individual results may vary depending on circumstances and the condition of patients.









Corporate Head Office:

Elekta AB (publ)

Box 7593, SE-103 93 Stockholm, Sweden

Tel +46 8 587 254 00 Fax +46 8 587 255 00 info@elekta.com

Regional Sales, Marketing and Service:

North America

Tel +1 770 300 9725 Fax +1 770 448 6338 info.america@elekta.com Europe, Middle East, Africa, Eastern Europe, Latin America

Tel +46 8 587 254 00 Fax +46 8 587 255 00 info.europe@elekta.com

Asia Pacific

Tel +852 2891 2208 Fax +852 2575 7133 info.asia@elekta.com

